Astra-Zeneca

Gefitinib (Iressa ) Astra-Zeneca TKI EGFR Metastatic non-small cell lung carcinoma... 

A831 Arrow Therapeutics/Astra Zeneca Phase 1... 

Principally because of its efficacy/tolerability ratio, prescriptions for quetiapine are growing faster than for any other atypical antipsychotic drug at present (personal communication, Astra Zeneca). 

Editor John Primeau Astra Zeneca Waitham Massachusetts... 

Crestor Astra-Zeneca) and lovastatin + niacin (Advicor Kos Pharmaceutical) — that can also cause rhabdomyolysis remain on the market. Although scientists agree that the other statins "seem to have essentially identical safety profiles and benefif-risk rafios," FDA said the ADRs associated with Baycol "have been reported significantly more frequently than for other approved statins." ... 

Very recently, the pharmaceutical group Astra-Zeneca proposed a screening strategy involving the use of both polysaccharide and macrocyclic glycopeptide columns. It is proposed to screen the compounds on seven different columns Chiralcel OD-H, Chiralpak AD, Chiralpak AS, Chiralcel... 

The present review illustrates that UV-vis based process analytical technology is widely discussed, but published examples are still scarce. The pharmaceutical industry, driven by the FDA s PAT initiative, can be seen as a forerunner. This is reflected by the observation that many references in this chapter are (co-) authored by representatives from pharmaceutical companies like Glaxo Wellcome and GlaxoSmithKline, ° " ° Astra Zeneca, Novartis and Eli Lilly. ... 

In 2004 Astra Zeneca published on a series of 4-anilinoquinazohnes as potent Src inhibitors [153]. One analog, AZM475271 (37), inhibited Src kinase activity with an IC50 of 10 nM, and had in vivo efficacy in a mouse model of pancreatic cancer [154] (Scheme 11). 

USAN Anastrozole Trade name Arimidex Astra-Zeneca PLC Launched 1995 M.W. 293.37... 

USAN Felodipine Trade name Piendil Astra-Zeneca Launched 1988 M.W. 384.26... 

Rosuvastatin (Crestor ) is the most recent HMG-CoA reductase inhibitor to be widely approved for the treatment of hypercholesterolemic patients. It has established an impressive record of clinical efficacy and is often prescribed to patients that do not respond well to earlier HMG-CoA reductase inhibitors (Schuster, 2003). This fully synthetic statin, developed by Astra-Zeneca and Shionogi Research Laboratories, has been shown to potently inhibit cholesterol biosynthesis in rat hepatocytyes (IC50 =1.12 nM). By comparison, pravastatin (5) was > 100-fold less active in the same assay (IC50 =198 nM) (Hirai et al., 1993 Watanabe et al., 1997). 

The development of the single enantiomer azole within the family of compounds used for gastrointestinal treatments is exemplified by Astra-Zeneca s Esomeprazole (a potent gastric acid secretion inhibitor) (Eigure 1.54). This development gave the impetus for the search for industrial chiral sulfoxidation catalysts. 

Astra Zeneca/CSK/Pfizer process chemistry prizes ACS CCI pharmaceutical roundtable research grants... 

Astra Zeneca, Three Biotech, One Innovation Drive, Worchester, MA 01605. Present address for J. M. Bristol-Myers Squibb, Pharmaceutical Research Institute, P. O. Box 4000, Princeton, NJ 08543. 

Kabi Vitrum, Stockholm, Sweden Roche Laboratories Inc., Nutley, New Jersey Astra Zeneca, Wilmington Delaware Bristol-Myers Squibb, Princeton, New Jersey Hospira, Lake Forest, Illinois InvensysAPV, Denmark MicroLuidics, Newton Massachusetts Five Star Technologies, Cleveland, Ohio Abitec Corp, Columbus, Ohio BASF, Mount Olive, New Jersey Sasol North America Inc., Houston, Texas Uniqema North America Inc., Chicago, Illinois Stepan Company, NorthLeld, Illinois Novartis Pharmaceuticals Corporation, East Hanover, New Jersey... 

Remacemide Noncompetitive antagonist Astra Zeneca Phase I Abandoned (Dyker and Lees, 1999)... 

Cangrelor (Astra Zeneca) is a P2T(P2YADP) purino-receptor antagonist and platelet aggregation inhibitor, This derivative is suitable for IV injection, The company is developing derivatives of this compound, Plasma half-life is five minutes and it achieves 90% inhibition of platelet aggregation with recovery 20 minutes after the end of the infusion,... 

Astra Zeneca s ZD 3523 (122),158 a potential leukotriene antagonist for the treatment of asthma, was prepared by an asymmetric hydrogenation of a 96 4 mixture of Z-4,4,4-trifluoro-2-methyl-2-butenoic acid (123) with a ruthenium/TMBTP catalyst (Scheme 12.49). This chemistry has been demonstrated at the multi-100-kg scale.87... 

Enzymes often prove to be the catalyst of choice for numerous transformations, and their prowess is particularly noteworthy for the synthesis of chiral molecules. The ability of biocatalysts to impart chirality through conversion of prochiral molecules or by transformation of only one stereoisomer of a racemic mixture stems from the inherent chirality of enzymes. As noted in the introduction to this book (Chapter 1), the chiral drug market is increasing, partly as a result of the need to produce single enantiomers as advocated by the U.S. Food and Drag Administration.1 The ability to extend the patent life of a drug through a racemic switch also plays a role in this increase. An example of a racemic switch is Astra Zeneca s Esomeprazole, a proton pump inhibitor (see Chapter 31).2... 

This contribution is dedicated in memory of Professor Dieter Sellman who left us far too soon. Financial support was provided by Zeneca Limited, through the Zeneca Strategic Research Fund. IEM is grateful to Zeneca for receiving the Zeneca Fellowship (1994-1997) and the 2003 Astra-Zeneca European Lectureship. 

Budesonide was originally developed by Astra Zeneca, but is now a generic compound. It exhibits prolonged residence in the lung tissues as a consequence of its increased lipophilic character resulting from the acetal group. 

In the area of metal catalyzed asymmetric sulfoxidation there is still much room for improvement. The most successful examples involve titanium tartrates, but at the same time often require near stoichiometric quantities of catalysts [301, 302]. Recently, this methodology has been successfully used for the production of (S)-Omeprazole by AstraZeneca [303] (see Fig. 4.110). A modified Kagan-pro-cedure [302] was applied, using cumene hydroperoxide as the oxidant. Another example is the sulfoxidation of an aryl ethyl sulfide, which was in development by Astra Zeneca as a candidate drug for the treatment of schizophrenia. In this case the final ee could be improved from 60% to 80% by optimising the Ti tar-trate ratio [304]. 

---